Drug Trial Radar · NCT05811351
A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Last checked: Nov 20, 2026Latest source record: Mar 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
305
Actual
Start
Mar 6, 2023
Primary completion
Feb 23, 2026
Study completion Feb 23, 2026
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Apr 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.
Conditions
- Geographic Atrophy
Interventions
JNJ-81201887Drug
JNJ-81201887 will be administered as intravitreal injection.
PrednisoneDrug
Prednisone will be administered as oral capsule.
PlaceboOther
Prednisone matching placebo will be administered as oral capsule.
TriamcinoloneDrug
Triamcinolone (corticosteroid injection) periocular injection will be administered as per local practice.
Sham ProcedureOther
Sham injections matching to single JNJ-81201887 injection and matching to corticosteroid (triamcinolone) periocular injection will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Global: Change From Baseline in Square Root of Geographic Atrophy (GA) Lesion Area in the Study Eye at Month 18Time frame: Baseline and Month 18
- United States (U.S.) Specific: Rate of Change in Untransformed GA Lesion Area in the Study EyeTime frame: Baseline to Month 18
Locations
162 sites in 17 countries. Site status is shown where the registry gives one.
Retinal Research Institute
Phoenix, Arizona
Retina Associates Southwest PC
Tucson, Arizona
Retina Consultants of Orange County
Fullerton, California
Retina Associates Of Southern California
Huntington Beach, California
Shiley Eye Institute Jacobs Retina Center
La Jolla, California
Jules Stein Eye Institute UCLA
Los Angeles, California
The Retina Partners
Los Angeles, California
California Retina Consultants
Oxnard, California
Stanford Health Care
Palo Alto, California
California Eye Medical Specialists
Pasadena, California
Retina Consultants San Diego
Poway, California
Retina Consultants of Southern California
Redlands, California
Bay Area Retina Associates
Walnut Creek, California
Colorado Retina - Lakewood Clinic
Lakewood, Colorado
Retina Group of Florida
Fort Lauderdale, Florida
National Opthalmic Research Institute
Fort Myers, Florida
VitreoRetinal Associates, PA
Gainesville, Florida
MedEye Associates
Miami, Florida
Retina Specialty Institute
Pensacola, Florida
Fort Lauderdale Eye Institute
Plantation, Florida
Retina Vitreous Associates of Florida
St. Petersburg, Florida
East Florida Eye Institute
Stuart, Florida
Georgia Retina
Marietta, Georgia
Marietta Eye Clinic
Marietta, Georgia
University Of Illinois
Chicago, Illinois
Retina Associates
Elmhurst, Illinois
University Retina
Lemont, Illinois
Midwest Eye Institute
Carmel, Indiana
Maine Eye Center
Portland, Maine
Retina Specialists
Baltimore, Maryland
The Retina Care Center
Baltimore, Maryland
The Retina Group of Washington
Chevy Chase, Maryland
Cumberland Valley Retina Consultants
Hagerstown, Maryland
Ophthalmic Consultants of Boston
Boston, Massachusetts
Vitreo Retinal Associates-Worcester
Worcester, Massachusetts
Foundation for Vision Research
Grand Rapids, Michigan
Associated Retinal Consultants P.C.
Royal Oak, Michigan
Retina Consultants of Minnesota
Saint Louis Park, Minnesota
The Retina Institute
St Louis, Missouri
Sierra Eye Associates
Reno, Nevada
Showing 40 of 162 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.